Here’s why the 4D Pharma (LON:DDDD) share price is surging today

This morning, the 4D Pharma share price erupted after management made an exciting announcement – so can the stock continue to climb higher?

| More on:
Smiling young man sitting in cafe and checking messages, with his laptop in front of him.

Image source: Getty Images

The 4D Pharma (LSE:DDDD) share price surged by nearly 10% this morning after management revealed the latest data from one of its five flagship clinical trials. Given the direction of the stock, I think it’s fair to say investors are pleased. But is this just a short-lived boost, or is this the start of a long-term growth explosion? Let’s dive in.

The driver behind the 4D Pharma share price

This morning the early-stage biopharmaceutical group released new data from its Phase 1/2 MRx-4DP0004 clinical trial. This is a new drug aimed at helping patients suffering from asthma. And the results were promising, to say the least.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Some 83.3% of patients who received the drug saw an improvement, and 50% of this group reduced their use of SABA inhalers. By comparison, these numbers drop to 56.3% and 18.8% respectively, for subjects who received a placebo.

Needless to say, it would appear the firm’s drug is working. And with no severe health side-effects detected, management has decided to proceed with the next stage of the clinical trial.

There are already plenty of asthma treatments available, which raises the barrier to commercialisation for this drug. Why? Because 4D Pharma will need to prove that its solution is better than what’s already available. It’s too soon to determine if this is the case. And we probably won’t find out until phase 3 trials begin.

However, suppose the results continue to be positive throughout the rest of development? In that case, the 4D Pharma share price jump today could be the start of an explosive long-term journey of growth. Why? Because asthma treatments have a multi-billion dollar addressable market size. And when compared to the group’s current £59m market capitalisation, the growth opportunity becomes crystal clear.

Taking a step back

As exciting as the explosive opportunity for the 4D Pharma share price is, there’s no guarantee of success. In fact, there’s already evidence of a potential problem.

All the data from clinical trials is gathered and analysed using complex statistical models that return something called a p-value. Without getting too deep into mathematics, a p-value essentially represents the probability of the results being wrong. And in the case of MRx-4DP0004, that probability is 8.8%.

Is that bad? No. Is it good enough? Also no. In most cases, medical regulators demand a p-value of less than 5%. And I don’t think it’s wise to assume 4D Pharma will be an exception. In other words, the clinical trial data from phases 2 and 3 need to be better for this treatment to have a chance of making it to market.

To buy, or not to buy?

This company is not a one-trick pony by any means. Like I said earlier, 4D Pharma has four other drugs in development that offer equally outstanding growth opportunities for its share price.

However, these other treatments are also in early-stage clinical trials. And it could be years before anything is ready to submit to regulators. That’s a long time for something to go wrong, especially since the group doesn’t generate any revenue at the moment.

Personally, I’m not going to be adding any shares to my portfolio today. But I will be keeping an eye on progress moving forward.

More on Investing Articles

Passive and Active: text from letters of the wooden alphabet on a green chalk board
Investing Articles

2 undervalued passive income stocks I’d buy today with £1,000

Falling stock prices are pushing up dividend yields. As a result, our author is looking for undervalued passive income stocks…

Read more »

Close-up of British bank notes
Investing Articles

2 cheap dividend shares I’d buy in a heartbeat

Our writer picks a pair of FTSE 100 dividend shares he would consider for his portfolio, that he thinks look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

With £500, I’d use the Warren Buffett method to find cheap shares

The legendary investor Warren Buffett has become a billionaire by following some key investment principles. Our writer explains why he…

Read more »

Man in a clothing store in a medical mask because of a coronovirus.
Investing Articles

Down 81%, are boohoo shares set for an explosive comeback?

boohoo shares have been falling rapidly. But could interest from a billion-dollar hedge fund cause a turnaround in 2022?

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

The Tullow Oil (TLW) share price jumps after losses! Is now the time to buy?

The Tullow Oil (TLW) share price ticked upwards on Thursday morning after falling nearly 30% over the last month. So,…

Read more »

Female analyst sat at desk looking at pie charts on paper
Investing Articles

Is the Lloyds share price about to dip below 40p?

The Lloyds share price has been trading below 50p for the better part of the year. But could the stock…

Read more »

Cheerful young businesspeople with laptop working in office
Investing Articles

2 beaten-down FTSE 250 shares I’m buying and holding for the long term

Andrew Woods explains why he's adding two FTSE 250 shares to his portfolio in the middle of a market sell-off.

Read more »

Female analyst sat at desk looking at pie charts on paper
Investing Articles

The Legal & General (LGEN) share price jumps 3%! Am I too late to buy?

The Legal & General (LGEN) share price soared in early trading on Thursday as the company registered a good start…

Read more »